Loading…

Adverse effects of anti-tuberculosis drugs on HepG2 cell bioenergetics

Tuberculosis (TB) is an intractable chronic infection. Disease treatment with anti-TB drugs remains challenging due to drug-induced hepatotoxicity. The toxicity of the anti-TB drugs rifampicin (RIF), isoniazid (INH) and pyrazinamide (PZA) either alone or in combination was investigated in HepG2 cell...

Full description

Saved in:
Bibliographic Details
Published in:Human & experimental toxicology 2017-06, Vol.36 (6), p.616-625
Main Authors: Elmorsy, E, Attalla, SM, Fikry, E, Kocon, A, Turner, R, Christie, D, Warren, A, Nwidu, LL, Carter, WG
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c407t-efcbfe5413e1fa57e0691b91e1d1c49644fa17fff4e2bf157e3f2134d50b4a963
cites cdi_FETCH-LOGICAL-c407t-efcbfe5413e1fa57e0691b91e1d1c49644fa17fff4e2bf157e3f2134d50b4a963
container_end_page 625
container_issue 6
container_start_page 616
container_title Human & experimental toxicology
container_volume 36
creator Elmorsy, E
Attalla, SM
Fikry, E
Kocon, A
Turner, R
Christie, D
Warren, A
Nwidu, LL
Carter, WG
description Tuberculosis (TB) is an intractable chronic infection. Disease treatment with anti-TB drugs remains challenging due to drug-induced hepatotoxicity. The toxicity of the anti-TB drugs rifampicin (RIF), isoniazid (INH) and pyrazinamide (PZA) either alone or in combination was investigated in HepG2 cells. Assays of intracellular adenosine triphosphate (ATP) levels at 4-, 24- and 48-h post-exposure to gradient concentrations of RIF, INH and PZA were conducted. Drug-induced effects on mitochondrial membrane potential (MMP), mitochondrial complex I and complex III activity, nicotinamide adenine dinucleotide (NAD+) levels and cellular lactate production were assessed. Decreased ATP levels were dose-dependent and correlated with drug exposure duration. Approximate 24-h IC50s were 0.5 mM, 70 mM and 84 mM for RIF, INH and PZA, respectively. Twenty-four hours post-drug treatment, reductions of MMP (p = 0.0005), mitochondrial complex I and III activities (p = 0.0001 and p = 0.0003, respectively), NAD+ levels (p = 0.0057) and increased lactate production (p < 0.0001) were observed. Drug combinations used to mimic cumulative drug treatments induced a synergistic inhibition of mitochondrial complex I activity. An assessment of cellular ultrastructure using transmission electron microscopy indicated drug-induced mitophagy. Collectively, our study suggests that hepatotoxicity of commonly employed anti-TB drugs is mediated by their curtailment of mitochondrial function.
doi_str_mv 10.1177/0960327116660751
format article
fullrecord <record><control><sourceid>proquest_AFRWT</sourceid><recordid>TN_cdi_proquest_journals_1902797515</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0960327116660751</sage_id><sourcerecordid>1902797515</sourcerecordid><originalsourceid>FETCH-LOGICAL-c407t-efcbfe5413e1fa57e0691b91e1d1c49644fa17fff4e2bf157e3f2134d50b4a963</originalsourceid><addsrcrecordid>eNp1kEFLw0AQhRdRbKzePUnA8-pMstllj6XYVih40XPIbmZLSprU3UTw37ulVUTwNIf3vfeGx9gtwgOiUo-gJeSZQpRSgirwjCUolOKgIT9nyUHmB33CrkLYAoDUBV6ySaaERACdsMWs_iAfKCXnyA4h7V1adUPDh9GQt2PbhyaktR83UerSFe2XWWqpbVPT9NSR39DQ2HDNLlzVBro53Sl7Wzy9zld8_bJ8ns_W3ApQAydnjaNCYE7oqkJRfAiNRsIardBSCFehcs4JyozDCOQuw1zUBRhRaZlP2f0xd-_795HCUG770XexskQNmdJxhCJScKSs70Pw5Mq9b3aV_ywRysNw5d_houXuFDyaHdU_hu-lIsCPQKg29Kv1v8AvzIV0fA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1902797515</pqid></control><display><type>article</type><title>Adverse effects of anti-tuberculosis drugs on HepG2 cell bioenergetics</title><source>Sage Journals GOLD Open Access 2024</source><creator>Elmorsy, E ; Attalla, SM ; Fikry, E ; Kocon, A ; Turner, R ; Christie, D ; Warren, A ; Nwidu, LL ; Carter, WG</creator><creatorcontrib>Elmorsy, E ; Attalla, SM ; Fikry, E ; Kocon, A ; Turner, R ; Christie, D ; Warren, A ; Nwidu, LL ; Carter, WG</creatorcontrib><description>Tuberculosis (TB) is an intractable chronic infection. Disease treatment with anti-TB drugs remains challenging due to drug-induced hepatotoxicity. The toxicity of the anti-TB drugs rifampicin (RIF), isoniazid (INH) and pyrazinamide (PZA) either alone or in combination was investigated in HepG2 cells. Assays of intracellular adenosine triphosphate (ATP) levels at 4-, 24- and 48-h post-exposure to gradient concentrations of RIF, INH and PZA were conducted. Drug-induced effects on mitochondrial membrane potential (MMP), mitochondrial complex I and complex III activity, nicotinamide adenine dinucleotide (NAD+) levels and cellular lactate production were assessed. Decreased ATP levels were dose-dependent and correlated with drug exposure duration. Approximate 24-h IC50s were 0.5 mM, 70 mM and 84 mM for RIF, INH and PZA, respectively. Twenty-four hours post-drug treatment, reductions of MMP (p = 0.0005), mitochondrial complex I and III activities (p = 0.0001 and p = 0.0003, respectively), NAD+ levels (p = 0.0057) and increased lactate production (p &lt; 0.0001) were observed. Drug combinations used to mimic cumulative drug treatments induced a synergistic inhibition of mitochondrial complex I activity. An assessment of cellular ultrastructure using transmission electron microscopy indicated drug-induced mitophagy. Collectively, our study suggests that hepatotoxicity of commonly employed anti-TB drugs is mediated by their curtailment of mitochondrial function.</description><identifier>ISSN: 0960-3271</identifier><identifier>EISSN: 1477-0903</identifier><identifier>DOI: 10.1177/0960327116660751</identifier><identifier>PMID: 27461009</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adenine ; Adenosine triphosphate ; Adenosine Triphosphate - metabolism ; Antitubercular Agents - toxicity ; ATP ; Bioenergetics ; Cellular manufacture ; Chronic infection ; Disease transmission ; Drug Interactions ; Drugs ; Electron microscopy ; Electron transport chain ; Electron Transport Complex I - metabolism ; Electron Transport Complex III - metabolism ; Energy Metabolism - drug effects ; Exposure ; Hep G2 Cells ; Hepatotoxicity ; Humans ; Isoniazid ; Isoniazid - toxicity ; Lactic acid ; Lactic Acid - metabolism ; Membrane potential ; Membrane Potential, Mitochondrial - drug effects ; Mitochondria ; NAD ; NAD - metabolism ; NADH-ubiquinone oxidoreductase ; Nicotinamide ; Nicotinamide adenine dinucleotide ; Pyrazinamide ; Pyrazinamide - toxicity ; Rifampin ; Rifampin - toxicity ; Side effects ; Studies ; Toxicity ; Transmission electron microscopy ; Tuberculosis ; Ultrastructure</subject><ispartof>Human &amp; experimental toxicology, 2017-06, Vol.36 (6), p.616-625</ispartof><rights>The Author(s) 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c407t-efcbfe5413e1fa57e0691b91e1d1c49644fa17fff4e2bf157e3f2134d50b4a963</citedby><cites>FETCH-LOGICAL-c407t-efcbfe5413e1fa57e0691b91e1d1c49644fa17fff4e2bf157e3f2134d50b4a963</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0960327116660751$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0960327116660751$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21966,27853,27924,27925,44945,45333</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.1177/0960327116660751?utm_source=summon&amp;utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27461009$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Elmorsy, E</creatorcontrib><creatorcontrib>Attalla, SM</creatorcontrib><creatorcontrib>Fikry, E</creatorcontrib><creatorcontrib>Kocon, A</creatorcontrib><creatorcontrib>Turner, R</creatorcontrib><creatorcontrib>Christie, D</creatorcontrib><creatorcontrib>Warren, A</creatorcontrib><creatorcontrib>Nwidu, LL</creatorcontrib><creatorcontrib>Carter, WG</creatorcontrib><title>Adverse effects of anti-tuberculosis drugs on HepG2 cell bioenergetics</title><title>Human &amp; experimental toxicology</title><addtitle>Hum Exp Toxicol</addtitle><description>Tuberculosis (TB) is an intractable chronic infection. Disease treatment with anti-TB drugs remains challenging due to drug-induced hepatotoxicity. The toxicity of the anti-TB drugs rifampicin (RIF), isoniazid (INH) and pyrazinamide (PZA) either alone or in combination was investigated in HepG2 cells. Assays of intracellular adenosine triphosphate (ATP) levels at 4-, 24- and 48-h post-exposure to gradient concentrations of RIF, INH and PZA were conducted. Drug-induced effects on mitochondrial membrane potential (MMP), mitochondrial complex I and complex III activity, nicotinamide adenine dinucleotide (NAD+) levels and cellular lactate production were assessed. Decreased ATP levels were dose-dependent and correlated with drug exposure duration. Approximate 24-h IC50s were 0.5 mM, 70 mM and 84 mM for RIF, INH and PZA, respectively. Twenty-four hours post-drug treatment, reductions of MMP (p = 0.0005), mitochondrial complex I and III activities (p = 0.0001 and p = 0.0003, respectively), NAD+ levels (p = 0.0057) and increased lactate production (p &lt; 0.0001) were observed. Drug combinations used to mimic cumulative drug treatments induced a synergistic inhibition of mitochondrial complex I activity. An assessment of cellular ultrastructure using transmission electron microscopy indicated drug-induced mitophagy. Collectively, our study suggests that hepatotoxicity of commonly employed anti-TB drugs is mediated by their curtailment of mitochondrial function.</description><subject>Adenine</subject><subject>Adenosine triphosphate</subject><subject>Adenosine Triphosphate - metabolism</subject><subject>Antitubercular Agents - toxicity</subject><subject>ATP</subject><subject>Bioenergetics</subject><subject>Cellular manufacture</subject><subject>Chronic infection</subject><subject>Disease transmission</subject><subject>Drug Interactions</subject><subject>Drugs</subject><subject>Electron microscopy</subject><subject>Electron transport chain</subject><subject>Electron Transport Complex I - metabolism</subject><subject>Electron Transport Complex III - metabolism</subject><subject>Energy Metabolism - drug effects</subject><subject>Exposure</subject><subject>Hep G2 Cells</subject><subject>Hepatotoxicity</subject><subject>Humans</subject><subject>Isoniazid</subject><subject>Isoniazid - toxicity</subject><subject>Lactic acid</subject><subject>Lactic Acid - metabolism</subject><subject>Membrane potential</subject><subject>Membrane Potential, Mitochondrial - drug effects</subject><subject>Mitochondria</subject><subject>NAD</subject><subject>NAD - metabolism</subject><subject>NADH-ubiquinone oxidoreductase</subject><subject>Nicotinamide</subject><subject>Nicotinamide adenine dinucleotide</subject><subject>Pyrazinamide</subject><subject>Pyrazinamide - toxicity</subject><subject>Rifampin</subject><subject>Rifampin - toxicity</subject><subject>Side effects</subject><subject>Studies</subject><subject>Toxicity</subject><subject>Transmission electron microscopy</subject><subject>Tuberculosis</subject><subject>Ultrastructure</subject><issn>0960-3271</issn><issn>1477-0903</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp1kEFLw0AQhRdRbKzePUnA8-pMstllj6XYVih40XPIbmZLSprU3UTw37ulVUTwNIf3vfeGx9gtwgOiUo-gJeSZQpRSgirwjCUolOKgIT9nyUHmB33CrkLYAoDUBV6ySaaERACdsMWs_iAfKCXnyA4h7V1adUPDh9GQt2PbhyaktR83UerSFe2XWWqpbVPT9NSR39DQ2HDNLlzVBro53Sl7Wzy9zld8_bJ8ns_W3ApQAydnjaNCYE7oqkJRfAiNRsIardBSCFehcs4JyozDCOQuw1zUBRhRaZlP2f0xd-_795HCUG770XexskQNmdJxhCJScKSs70Pw5Mq9b3aV_ywRysNw5d_houXuFDyaHdU_hu-lIsCPQKg29Kv1v8AvzIV0fA</recordid><startdate>201706</startdate><enddate>201706</enddate><creator>Elmorsy, E</creator><creator>Attalla, SM</creator><creator>Fikry, E</creator><creator>Kocon, A</creator><creator>Turner, R</creator><creator>Christie, D</creator><creator>Warren, A</creator><creator>Nwidu, LL</creator><creator>Carter, WG</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7ST</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>SOI</scope></search><sort><creationdate>201706</creationdate><title>Adverse effects of anti-tuberculosis drugs on HepG2 cell bioenergetics</title><author>Elmorsy, E ; Attalla, SM ; Fikry, E ; Kocon, A ; Turner, R ; Christie, D ; Warren, A ; Nwidu, LL ; Carter, WG</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c407t-efcbfe5413e1fa57e0691b91e1d1c49644fa17fff4e2bf157e3f2134d50b4a963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adenine</topic><topic>Adenosine triphosphate</topic><topic>Adenosine Triphosphate - metabolism</topic><topic>Antitubercular Agents - toxicity</topic><topic>ATP</topic><topic>Bioenergetics</topic><topic>Cellular manufacture</topic><topic>Chronic infection</topic><topic>Disease transmission</topic><topic>Drug Interactions</topic><topic>Drugs</topic><topic>Electron microscopy</topic><topic>Electron transport chain</topic><topic>Electron Transport Complex I - metabolism</topic><topic>Electron Transport Complex III - metabolism</topic><topic>Energy Metabolism - drug effects</topic><topic>Exposure</topic><topic>Hep G2 Cells</topic><topic>Hepatotoxicity</topic><topic>Humans</topic><topic>Isoniazid</topic><topic>Isoniazid - toxicity</topic><topic>Lactic acid</topic><topic>Lactic Acid - metabolism</topic><topic>Membrane potential</topic><topic>Membrane Potential, Mitochondrial - drug effects</topic><topic>Mitochondria</topic><topic>NAD</topic><topic>NAD - metabolism</topic><topic>NADH-ubiquinone oxidoreductase</topic><topic>Nicotinamide</topic><topic>Nicotinamide adenine dinucleotide</topic><topic>Pyrazinamide</topic><topic>Pyrazinamide - toxicity</topic><topic>Rifampin</topic><topic>Rifampin - toxicity</topic><topic>Side effects</topic><topic>Studies</topic><topic>Toxicity</topic><topic>Transmission electron microscopy</topic><topic>Tuberculosis</topic><topic>Ultrastructure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Elmorsy, E</creatorcontrib><creatorcontrib>Attalla, SM</creatorcontrib><creatorcontrib>Fikry, E</creatorcontrib><creatorcontrib>Kocon, A</creatorcontrib><creatorcontrib>Turner, R</creatorcontrib><creatorcontrib>Christie, D</creatorcontrib><creatorcontrib>Warren, A</creatorcontrib><creatorcontrib>Nwidu, LL</creatorcontrib><creatorcontrib>Carter, WG</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Environment Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Environment Abstracts</collection><jtitle>Human &amp; experimental toxicology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Elmorsy, E</au><au>Attalla, SM</au><au>Fikry, E</au><au>Kocon, A</au><au>Turner, R</au><au>Christie, D</au><au>Warren, A</au><au>Nwidu, LL</au><au>Carter, WG</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adverse effects of anti-tuberculosis drugs on HepG2 cell bioenergetics</atitle><jtitle>Human &amp; experimental toxicology</jtitle><addtitle>Hum Exp Toxicol</addtitle><date>2017-06</date><risdate>2017</risdate><volume>36</volume><issue>6</issue><spage>616</spage><epage>625</epage><pages>616-625</pages><issn>0960-3271</issn><eissn>1477-0903</eissn><abstract>Tuberculosis (TB) is an intractable chronic infection. Disease treatment with anti-TB drugs remains challenging due to drug-induced hepatotoxicity. The toxicity of the anti-TB drugs rifampicin (RIF), isoniazid (INH) and pyrazinamide (PZA) either alone or in combination was investigated in HepG2 cells. Assays of intracellular adenosine triphosphate (ATP) levels at 4-, 24- and 48-h post-exposure to gradient concentrations of RIF, INH and PZA were conducted. Drug-induced effects on mitochondrial membrane potential (MMP), mitochondrial complex I and complex III activity, nicotinamide adenine dinucleotide (NAD+) levels and cellular lactate production were assessed. Decreased ATP levels were dose-dependent and correlated with drug exposure duration. Approximate 24-h IC50s were 0.5 mM, 70 mM and 84 mM for RIF, INH and PZA, respectively. Twenty-four hours post-drug treatment, reductions of MMP (p = 0.0005), mitochondrial complex I and III activities (p = 0.0001 and p = 0.0003, respectively), NAD+ levels (p = 0.0057) and increased lactate production (p &lt; 0.0001) were observed. Drug combinations used to mimic cumulative drug treatments induced a synergistic inhibition of mitochondrial complex I activity. An assessment of cellular ultrastructure using transmission electron microscopy indicated drug-induced mitophagy. Collectively, our study suggests that hepatotoxicity of commonly employed anti-TB drugs is mediated by their curtailment of mitochondrial function.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>27461009</pmid><doi>10.1177/0960327116660751</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier ISSN: 0960-3271
ispartof Human & experimental toxicology, 2017-06, Vol.36 (6), p.616-625
issn 0960-3271
1477-0903
language eng
recordid cdi_proquest_journals_1902797515
source Sage Journals GOLD Open Access 2024
subjects Adenine
Adenosine triphosphate
Adenosine Triphosphate - metabolism
Antitubercular Agents - toxicity
ATP
Bioenergetics
Cellular manufacture
Chronic infection
Disease transmission
Drug Interactions
Drugs
Electron microscopy
Electron transport chain
Electron Transport Complex I - metabolism
Electron Transport Complex III - metabolism
Energy Metabolism - drug effects
Exposure
Hep G2 Cells
Hepatotoxicity
Humans
Isoniazid
Isoniazid - toxicity
Lactic acid
Lactic Acid - metabolism
Membrane potential
Membrane Potential, Mitochondrial - drug effects
Mitochondria
NAD
NAD - metabolism
NADH-ubiquinone oxidoreductase
Nicotinamide
Nicotinamide adenine dinucleotide
Pyrazinamide
Pyrazinamide - toxicity
Rifampin
Rifampin - toxicity
Side effects
Studies
Toxicity
Transmission electron microscopy
Tuberculosis
Ultrastructure
title Adverse effects of anti-tuberculosis drugs on HepG2 cell bioenergetics
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T00%3A52%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adverse%20effects%20of%20anti-tuberculosis%20drugs%20on%20HepG2%20cell%20bioenergetics&rft.jtitle=Human%20&%20experimental%20toxicology&rft.au=Elmorsy,%20E&rft.date=2017-06&rft.volume=36&rft.issue=6&rft.spage=616&rft.epage=625&rft.pages=616-625&rft.issn=0960-3271&rft.eissn=1477-0903&rft_id=info:doi/10.1177/0960327116660751&rft_dat=%3Cproquest_AFRWT%3E1902797515%3C/proquest_AFRWT%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c407t-efcbfe5413e1fa57e0691b91e1d1c49644fa17fff4e2bf157e3f2134d50b4a963%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1902797515&rft_id=info:pmid/27461009&rft_sage_id=10.1177_0960327116660751&rfr_iscdi=true